Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.

MLA

McCarthy, James S., et al. “Safety, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Eukaryotic Translation Elongation Factor 2 Inhibitor M5717: A First-in-Human, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study and Volunteer Infection Study.” The Lancet. Infectious Diseases, vol. 21, no. 12, Dec. 2021, pp. 1713–24. EBSCOhost, https://doi.org/10.1016/S1473-3099(21)00252-8.

APA

McCarthy, J. S., Yalkinoglu, Ö., Odedra, A., Webster, R., Oeuvray, C., Tappert, A., Bezuidenhout, D., Giddins, M. J., Dhingra, S. K., Fidock, D. A., Marquart, L., Webb, L., Yin, X., Khandelwal, A., & Bagchus, W. M. (2021). Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. The Lancet. Infectious Diseases, 21(12), 1713–1724. https://doi.org/10.1016/S1473-3099(21)00252-8

Chicago

McCarthy, James S, Özkan Yalkinoglu, Anand Odedra, Rebecca Webster, Claude Oeuvray, Aliona Tappert, Deon Bezuidenhout, et al. 2021. “Safety, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Eukaryotic Translation Elongation Factor 2 Inhibitor M5717: A First-in-Human, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study and Volunteer Infection Study.” The Lancet. Infectious Diseases 21 (12): 1713–24. doi:10.1016/S1473-3099(21)00252-8.